Understanding Gut Health and Treatment for Drug-Resistant Tuberculosis
Official title: Longitudinal microbiome-host interactions and clinical outcomes in drug-resistant tuberculosis patients
Funded at Stellenbosch University · NIH-11122188 · Data updated 2026-11-12
This project looks at how gut bacteria change during treatment for drug-resistant tuberculosis to help us understand patient health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stellenbosch University NIH-funded |
| Lab location | 1 site (Stellenbosch, SOUTH AFRICA) |
| Project start | July 27, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $89,253 |
| NIH project number | 5K43TW012302-04 |
| Project ID | NIH-11122188 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults and adolescents (15 years or older) with rifampicin-resistant or multidrug-resistant tuberculosis who are starting a specific shorter course treatment regimen.
✕Less likely to help
Patients who do not have drug-resistant tuberculosis or are not receiving the specific shorter course regimen would not directly benefit from this particular research.
What this research studies
Our bodies have many tiny living organisms, called the microbiome, which are important for our health, especially in the gut. We know that certain gut compounds can affect the risk of developing tuberculosis (TB), a serious illness. This project will follow patients with drug-resistant TB in South Africa as they receive a new treatment. We will collect samples like sputum and stool to see how their microbiome changes over time and how these changes relate to their health outcomes.
Why it matters
Potential benefit: If successful, this work could help us understand how to improve treatment outcomes for drug-resistant tuberculosis patients by supporting their gut health.
How similar studies have gone: While the general impact of antibiotics on the microbiome is known, the specific effects of this new drug-resistant TB treatment on the microbiome in these patients are currently uncharacterized.
Where this research is happening
-
Stellenbosch University
Stellenbosch, South Africa Active
Researchers
- Principal investigator: Naidoo, Charissa Camille — Stellenbosch University
- Study coordinator: Naidoo, Charissa Camille
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Pulmonary rehabilitation to reduce breathing problems after tuberculosis
A program of guided exercise and breathing training to help adults who have recovered from TB breathe better and feel healthier.
-
Pulmonary rehab to reduce breathing troubles after TB
A program of pulmonary rehabilitation is being studied to help adults who have completed TB treatment avoid ongoing lung problems and improve daily breathing.
-
Air pollution and tuberculosis spread in Kampala, Uganda
This project looks at whether dirty air from PM2.5 particles makes tuberculosis more likely to spread within urban slum households in Kampala, Uganda.
-
Air pollution and TB spread in Ugandan urban slums
This project explores whether exposure to air pollution makes tuberculosis more likely to spread within households in a crowded Ugandan slum.
-
Air pollution and TB transmission in Kampala’s urban slums
This project looks at whether air pollution from PM2.5 makes tuberculosis spread more easily from infected people to their neighbors in urban slums of Kampala, Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.